10-K: Arbutus Biopharma Reports 2024 Financial Results and Provides Business Update

Arbutus Biopharma focuses on advancing its hepatitis B programs and LNP delivery technology while streamlining operations and reducing workforce.

Summary

• Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases, particularly chronic hepatitis B (cHBV).
• The company is developing imdusiran (AB-729) and AB-101 for cHBV treatment and maximizing its Lipid Nanoparticle (LNP) delivery technology.
• Arbutus is involved in patent infringement lawsuits against Moderna and Pfizer/BioNTech regarding their use of Arbutus' LNP technology in COVID-19 vaccines.
• A trial date for the Moderna lawsuit in the United States is set for September 24, 2025.
• Five international lawsuits against Moderna have been filed in March 2025.
• The claim construction hearing for the Pfizer/BioNTech lawsuit occurred in December 2024, with a ruling expected in 2025.
• In 2024, Arbutus streamlined operations by ceasing discovery efforts, discontinuing the IM-PROVE III clinical trial, and reducing the workforce by 40%.
• In Q1 2025, the company appointed new board members, a new CEO, and a new CFO, and further reduced the workforce by 57%, resulting in 19 employees.
• Arbutus expects a one-time restructuring charge of $11 million to $13 million in Q1 2025 due to these changes.
• The new management team is reviewing the pipeline and development plans for hepatitis B programs.
• The company's strategy focuses on maximizing opportunities for cHBV programs and LNP delivery technology.
• Arbutus is committed to defending its intellectual property related to LNP technology.
• The company's HBV strategy aims to develop a functional cure for cHBV patients using imdusiran as a cornerstone in combination therapy.
• Imdusiran is a subcutaneously-delivered RNAi therapeutic that suppresses HBV antigens.
• AB-101 is an oral PD-L1 inhibitor that aims to reawaken patients' HBV-specific immune response.
• Clinical data from the IM-PROVE I Phase 2a trial showed a 50% functional cure rate in HBeAg-negative patients with baseline HBsAg levels less than 1000 IU/mL when combining imdusiran with Peg-IFN-2a and NA therapy.
• Data from the IM-PROVE II trial showed that adding low dose nivolumab increased rates of HBsAg loss in cHBV patients, with 23% achieving HBsAg loss by week 48.
• Arbutus has a technology transfer and license agreement with Qilu Pharmaceutical for imdusiran in Greater China and Taiwan.
• Arbutus has royalty entitlements to Alnylam's global net sales of ONPATTRO, with a portion of the royalty interest sold to OMERS.
• As of December 31, 2024, Arbutus owned approximately 16% of the common equity of Genevant, with a carrying value of zero.
• As of December 31, 2024, Arbutus had cash, cash equivalents, and investments in marketable securities of $122.6 million.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive clinical trial results and a focus on key programs, the company is still operating at a loss, undergoing restructuring, and facing significant competition and risks.

Positives

• Positive clinical data from IM-PROVE I Phase 2a trial shows promising functional cure rates with imdusiran combination therapy.
• The company is actively pursuing patent infringement lawsuits to protect its intellectual property.
• Streamlining operations and reducing workforce are expected to significantly reduce net cash burn in 2025.
• New management team and board of directors are reviewing the pipeline and development plans for hepatitis B programs.
• The company has a technology transfer and license agreement with Qilu Pharmaceutical for imdusiran in Greater China and Taiwan.
• Arbutus has royalty entitlements to Alnylam's global net sales of ONPATTRO.

Negatives

• The company has incurred losses in nearly every year since its inception and does not expect to achieve profits for the foreseeable future.
• ONPATTRO sales have declined each of the last two years due primarily to sales from Alnylams next generation RNAi product AMVUTTRA cannibalizing sales of ONPATTRO.
• The company is involved in multiple patent infringement lawsuits in multiple jurisdictions to protect and assert its intellectual property rights against large, well-capitalized companies, which requires that we continue to expend substantial resources, and we may not be successful in these proceedings.
• The company expects a one-time restructuring charge of $11 million to $13 million in Q1 2025.

Risks

• The outcomes of clinical trials are uncertain, and delays in the completion of or the termination of any clinical trial of our product candidates could harm our business, financial condition and prospects.
• The company may require substantial additional capital to fund its operations, and additional funds may be dilutive to shareholders or impose operational restrictions.
• The company faces significant competition from other biotechnology and pharmaceutical companies targeting HBV.
• The company is largely dependent on the future commercial success of its HBV product candidates.
• The company depends on Qilu for the development and commercialization of imdusiran in China, Hong Kong, Macau and Taiwan.
• The company is involved in multiple patent infringement lawsuits in multiple jurisdictions to protect and assert its intellectual property rights against large, well-capitalized companies, which requires that we continue to expend substantial resources, and we may not be successful in these proceedings.

Future Outlook

The company expects to significantly reduce its net cash burn in 2025 compared to 2024 and is reviewing its pipeline and development plans for hepatitis B programs.

Management Comments

• The new Board and management team are reviewing our pipeline and development plans for our hepatitis B programs.
• To assist with this review, we are currently retaining experts in virology, hepatitis B, and in the clinical development and approval of antiviral treatments.
• We expect to provide a further update once our review is complete.

Industry Context

The report acknowledges significant competition in the HBV market from both large and small pharmaceutical companies, highlighting the need for Arbutus to successfully complete clinical trials, obtain regulatory approvals, and effectively market any approved products.

Comparison to Industry Standards

• The report mentions several competitors, including GlaxoSmithKline, Gilead Sciences, Assembly, Aligos Therapeutics, Bluejay Therapeutics, Inc., AusperBio Therapeutics, Inc. and Brii Biosciences Ltd., but does not provide a detailed comparison of Arbutus' results to specific industry benchmarks.
• The report notes that the company achieved a 50% functional cure rate in a subset of patients in the IM-PROVE I Phase 2a trial using imdusiran in combination with other agents, but does not provide a detailed comparison of this result to other similar trials in the HBV field.

Management Changes

Legal Proceedings

• Arbutus and Genevant filed patent infringement lawsuits against Moderna and Pfizer/BioNTech regarding their use of Arbutus' LNP technology in COVID-19 vaccines.
• A trial date for the Moderna lawsuit in the United States is set for September 24, 2025.
• Five international lawsuits against Moderna have been filed in March 2025.
• The claim construction hearing for the Pfizer/BioNTech lawsuit occurred in December 2024, with a ruling expected in 2025.

Stakeholder Impact

• Shareholders will be impacted by the company's restructuring, potential dilution from future financing, and the outcome of patent litigation.
• Employees have been impacted by workforce reductions.
• Customers (potential patients) may benefit from the company's focus on developing new treatments for HBV.
• Suppliers and contractors may be impacted by the company's streamlining of operations and changes in research and development activities.

Next Steps

• The new management team will continue to review the pipeline and development plans for hepatitis B programs.
• The company will continue to pursue patent infringement lawsuits against Moderna and Pfizer/BioNTech.
• The company will continue to advance the clinical development of imdusiran and AB-101.

Key Dates

Keywords

Arbutus Biopharma, Hepatitis B, Imdusiran, AB-729, AB-101, LNP technology, Patent infringement, Clinical trials, Qilu Pharmaceutical, ONPATTRO, Alnylam, Genevant, Financial results, Biopharmaceutical